TABLE 4.
Performance of Vitek-2 AST-GP80 card for Staphylococcus pseudintermedius in comparison to the disk diffusion methoda,b
| Drug | CA (no. [%]) | κ | VME (no. [%]) | ME (no. [%]) | MiE (no. [%]) |
|---|---|---|---|---|---|
| OXA | 79/80 (98.75) | 0.97 | 0/31 (0.00) | 1/49 (2.04) | 0/80 (0.00) |
| AMC | 80/80 (100.00) | 1.00 | 0/20 (0.00) | 0/60 (0.00) | 0/80 (0.00) |
| CEF | 77/80 (96.25) | 0.90 | 0/17 (0.00) | 0/61 (0.00) | 3/80 (3.75) |
| GEN | 76/80 (95.00) | 0.89 | 2/21 (9.52) | 0/53 (0.00) | 2/80 (2.50) |
| ENR | 72/80 (90.00) | 0.80 | 0/23 (0.00) | 0/55 (0.00) | 8/80 (10.00) |
| DOX | 75/80 (93.75) | 0.87 | 0/0 (NA) | 0/53 (0.00) | 5/80 (6.25) |
| CLI | 68/80 (85.00) | 0.70 | 5/32 (15.63) | 1/40 (2.50) | 7/80 (8.75) |
| ICR | 74/80 (92.50) | 0.76 | 1/13 (7.69) | 5/67 (7.46) | 0/80 (0.00) |
| SXT | 80/80 (100.00) | 1.00 | 0/37 (0.00) | 0/43 (0.00) | 0/80 (0.00) |
a
Agreements of below 90% are shown in boldface type.
b
Abbreviations: CA, categorical agreement; κ, kappa coefficient; VME, very major error; ME, major error; MiE, minor error; OXA, oxacillin; AMC, amoxicillin/clavulanate; CEF, cephalothin; GEN, gentamicin; ENR, enrofloxacin; DOX, doxycycline; CLI, clindamycin; ICR, inducible clindamycin resistance; SXT, trimethoprim-sulfamethoxazole; MUP, mupirocin; NA, not applicable.